Carbon 14 and Carbon 13 Syntheses of Velagliflozin

Bachir Latli; Matt J Hrapchak; Maxim Chevliakov; Chutian Shu

doi:10.1002/jlcr.4091

Carbon 14 and Carbon 13 Syntheses of Velagliflozin

J Labelled Comp Radiopharm. 2024 May 15;67(5):180-185. doi: 10.1002/jlcr.4091. Epub 2024 Apr 11.

Authors

Bachir Latli¹, Matt J Hrapchak¹, Maxim Chevliakov¹, Chutian Shu¹

Affiliation

¹ The Radiosynthesis Laboratory, Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA.

PMID: 38605481
DOI: 10.1002/jlcr.4091

Abstract

Velagliflozin is the active ingredient of the first oral liquid medication approved by the Food and Drug Administration for the treatment of diabetes in cats. This compound belongs to the known class of sodium-glucose cotransporter 2 inhibitors approved to treat diabetes in human. Here, we report the detailed synthesis of velagliflozin labeled with carbon 14 and carbon 13.

Keywords: animal health; carbon 13; carbon 14; diabetes; radiosynthesis; velagliflozin.

MeSH terms

Benzhydryl Compounds
Carbon Isotopes* / chemistry
Carbon Radioisotopes* / chemistry
Chemistry Techniques, Synthetic
Glucosides / chemical synthesis
Glucosides / chemistry
Glucosides / pharmacology
Sodium-Glucose Transporter 2 Inhibitors / chemical synthesis
Sodium-Glucose Transporter 2 Inhibitors / chemistry
Sodium-Glucose Transporter 2 Inhibitors / pharmacology

Substances

Carbon Radioisotopes
Carbon-14
Carbon-13
Carbon Isotopes
Glucosides
6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-triol
Sodium-Glucose Transporter 2 Inhibitors
Benzhydryl Compounds